Jinyi Xu | Medicinal Chemistry | Best Researcher Award

Published on by China Scientist

Prof. Dr. Jinyi Xu | Medicinal Chemistry | Best Researcher Award 

Prof. Jinyi Xu is a professor of Medicinal Chemistry at China Pharmaceutical University. She earned her B.S. and Ph.D. from the same university and completed a postdoctoral fellowship at Kinki University, Japan. Her research focuses on the design and synthesis of novel drug candidates, natural product modification, and targeted protein degradation strategies like PROTACs and HyT. She has led over 10 major research projects, holds more than 40 patents, and has published over 200 peer-reviewed papers. Prof. Xu is also an Associate Editor of Bioorganic Chemistry and an active member of several national pharmaceutical committees.

Prof. Dr. Jinyi Xu | China Pharmaceutical University | China

Profile 

https://www.scopus.com/authid/detail.uri?authorId=8445708700

ORCID ID

🎓Education

  • Prof. Jinyi Xu obtained both her Bachelor of Science degree in Pharmacology in 1986 and her Doctorate in Medicinal Chemistry in 2001 from China Pharmaceutical University. Following her Ph.D., she pursued a postdoctoral fellowship at Kinki University in Japan, further strengthening her academic foundation in medicinal chemistry and drug discovery.

👨‍🏫Experience

  • Prof. Xu began her academic career at China Pharmaceutical University, where she was promoted to Associate Professor in 1999 and then to Full Professor in 2007. She currently serves as a Professor in the Department of Medicinal Chemistry, where she leads a dynamic research group as Principal Investigator. Her experience spans over three decades in medicinal chemistry, with an emphasis on natural product-based drug design and development.

🤝Awards and Honors

  • Prof. Xu has been recognized for her substantial contributions to pharmaceutical sciences in China. One of her most notable achievements includes the advancement of a candidate compound into Phase II clinical development. She is also an Associate Editor for the journal Bioorganic Chemistry, reflecting her standing in the global research community. Her significant participation as a committee member of the New Drug Evaluation Committee further demonstrates her influence in national drug assessment and development efforts.

💡Skills and Certifications

  • Prof. Xu brings extensive expertise in medicinal chemistry, natural product derivatization, structure-activity relationship (SAR) studies, and innovative drug design strategies. Her technical strengths lie in multi-target drug discovery, mechanism-based evaluation, and the translation of synthetic compounds into clinical drug candidates. She also possesses strong leadership and collaborative skills, evident through her ongoing partnerships with international researchers in the USA and UK, and her involvement in both academic and industry-led pharmaceutical innovation.

🔬Research Focus

  • Prof. Xu’s research is centered on the design and synthesis of novel drug candidates, structural modification of natural products, and the development of innovative therapeutic modalities such as PROTAC (proteolysis-targeting chimeras) and HyT (hydrophobic tagging) degraders. Her work particularly addresses therapeutic areas like hypertension, cancer, and Alzheimer’s disease. Her current research projects funded by the National Natural Science Foundation of China focus on degradation-based therapeutic strategies and prodrug design using bioorthogonal chemistry.

🌎Conclusion

  • Prof. Jinyi Xu is a role model for scientific excellence. Her exceptional contributions to medicinal chemistry and drug discovery make her a deserving recipient of the Research for Best Researcher Award. Her achievements not only reflect academic distinction but also drive real-world solutions to pressing medical challenges.

📖Publications

  • Novel agents derived from natural product β-elemene: A second round of design and synthesis to enhance antitumor properties
    Authors: Liu Zhouyan, Li Tong, Gu Chenglei, Xu Jingyi, Chen Jichao
    Journal: Bioorganic and Medicinal Chemistry, 2025

  •  In Vivo Self-Assembly of PROTACs by Bioorthogonal Chemistry for Precision Cancer Therapy
    Authors: Xie Shaowen, Zhu Jingjie, Peng Yihan, Su Zhigui, Xu Shengtao
    Journal: Angewandte Chemie International Edition, 2025

  • Discovery of hematopoietic progenitor kinase 1 inhibitors using machine learning-based screening and free energy perturbation
    Authors: Feng Dazhi, Liu Bo, Chen Zhiwei, Ai Jing, Zhang Hefeng
    Journal: Journal of Biomolecular Structure and Dynamics, 2025

  • Design, synthesis, and biological evaluation of novel HPK1 inhibitors possessing 3-cyano-quinoline moiety
    Authors: Chen Long, Zhang Baixue, Zhou Pijun, Yao Hong, Xu Jingyi
    Journal: Bioorganic Chemistry, 2024

  • Palladium-Mediated Bioorthogonal System for Prodrug Activation of N-Benzylbenzamide-Containing Tubulin Polymerization Inhibitors for the Treatment of Solid Tumors
    Authors: Li Jinlong, Zhang Tong, Wu Di, Xu Jingyi, Xu Shengtao
    Journal: Journal of Medicinal Chemistry, 2024

hi

Jinming Zhou | Medicinal Chemistry | Best Researcher Award

Published on by China Scientist

Dr. Jinming Zhou | Medicinal Chemistry| Best Researcher Award

Research and Grant Success:

  • Dr. Zhou’s research has been consistently supported by prestigious National Natural Science Foundation (NCSF) grants, with four approvals to date. This grant success not only reflects the high quality and impact of his research but also indicates his capacity to conduct rigorous and relevant studies that address critical health challenges.
Dr. Jinming Zhou, Zhejiang Normal University , China

Profile

Scopus

OrcID

🌱EARLY ACADEMIC PURSUITS

  • Dr. Zhou’s academic journey began at Beijing Normal University, where he earned his Bachelor of Science (B.S.) in 2000 and Master of Science (M.S.) in 2003. His passion for rational drug design led him to pursue a Ph.D. at the Shanghai Institute of Organic Chemistry, where he specialized in this field, establishing a strong foundation in medicinal chemistry. Postdoctoral training followed at McGill University in Canada, where he continued advancing in rational drug design and gained international research exposure.

💼 PROFESSIONAL ENDEAVORS

  • In 2010, Dr. Zhou joined the Institute of Medicinal Biotechnology at the Chinese Academy of Medical Science as an Associate Professor. Demonstrating outstanding contributions in drug research, he achieved full professorship in 2017. His career took a new turn in 2018 when he accepted a professorship at Zhejiang Normal University, where he also became the Director of the Drug Development and Innovation Center. Dr. Zhou’s leadership at this center has been pivotal in establishing innovative practices and groundbreaking projects.

🔬CONTRIBUTIONS AND RESEARCH FOCUS 

  • Dr. Zhou’s research team is at the forefront of developing anti-viral and anti-cancer drugs. His group combines rational drug design and applied medicinal research to create effective therapeutic solutions. His work has a special emphasis on translational medicine, aiming to bridge scientific research and clinical applications. He has secured four prestigious National Natural Science Foundation (NCSF) grants, supporting his work in advancing therapeutic drug development.

📚ACADEMIC CITES 

  • With over a hundred publications, Dr. Zhou has significantly impacted medicinal chemistry, particularly in antiviral and anticancer drug design. His research has become a widely cited reference in related studies, underscoring his scientific contributions’ value and relevance.

🌍IMPACT AND INFLUENCE

  • Dr. Zhou’s influence in the medicinal chemistry field is highlighted by his 100+ publications in high-impact journals, showcasing the scientific community’s recognition of his expertise. His achievements were honored in 2012 with the prestigious “Xiehe Star” award, recognizing his exceptional contributions to the field of drug design.

🌟LEGACY AND FUTURE AND CONTRIBUTIONS

  • As Dr. Zhou continues his work at the Drug Development and Innovation Center, he is shaping a new generation of researchers focused on tackling global health challenges. His legacy is built not only on his published works but also on his mentorship and role in expanding the field of drug innovation. His ongoing research promises to further the understanding of rational drug design and its applications in combating complex diseases.

📄Publications

  • “Inducing or enhancing protein-protein interaction to develop drugs: Molecular glues with various biological activity”
    Authors: Zhang, R., Zheng, Y., Xiang, F., Zhou, J.
    Journal: European Journal of Medicinal Chemistry, 2024, 277, 116756
  • “METTL3 inhibitor suppresses the progression of prostate cancer via IGFBP3/AKT pathway and synergizes with PARP inhibitor”
    Authors: Chen, X., Wang, M., Wang, H., Zhou, J., Wu, M.
    Journal: Biomedicine and Pharmacotherapy, 2024, 179, 117366
  • “Autophagy mediated targeting degradation, a promising strategy in drug development”
    Authors: Zhang, J., Pan, X., Ji, W., Zhou, J.
    Journal: Bioorganic Chemistry, 2024, 149, 107466
  • “A novel hydrophobic tag leads to the efficient degradation of programmed death-ligand 1”
    Authors: Gao, J., Xie, Y., Zhang, J., Cen, S., Zhou, J.
    Journal: RSC Medicinal Chemistry, 2024, 15(9), pp. 3038–3047
  • “Design and Synthesis of Dual-Target Inhibitors Targeting Androgen Receptors and Glucocorticoid Receptors to Overcome Antiandrogen Resistance in Castration-Resistant Prostate Cancer”
    Authors: Li, C., Han, X., Yan, Q., Wu, M., Zhou, J.
    Journal: Journal of Medicinal Chemistry, 2024, 67(5), pp. 3419–3436